Moderna (NASDAQ: MRNA) has become a well-known name in healthcare over the past few years thanks to its COVID-19 vaccine. Moderna has very high hopes, but are they too good to be true? To say Moderna has an aggressive growth plan would be an understatement.
Sanofi is all in on AI and thinks it could help alleviate patent timeline pressures from the Inflation Reduction Act.
The Biden administration will be providing $600 million to fund the production of new at-home COVID-19 tests as U.S. cases tick higher. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the status of new vaccines in development and how the U.S. may be responding to new variant strains. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.